CYP2C9*2 allele increases risk for hypoglycemia in POR*1/*1 type 2 diabetic patients treated with sulfonylureas

Experimental and Clinical Endocrinology and Diabetes

Volumn 122, Issue 1, 2014, Pages 60-63

  Ragia, G ^a   Tavridou, A ^a,b   Elens, L ^c,d   Van Schaik, R H N ^d   Manolopoulos, V G ^a,b  

^a DEMOCRITUS UNIVERSITY OF THRACE MEDICAL SCHOOL   (Greece)

^b Academic General Hospital Alexandroupolis   (Greece)

^c UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

^d ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

CYP2C92; hypoglycemia; pharmacogenetics; POR28; sulfonylurea

Indexed keywords

CYTOCHROME P450 2C9; CYTOCHROME P450 REDUCTASE; SULFONYLUREA; ANTIDIABETIC AGENT; CYP2C9 PROTEIN, HUMAN; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE FERRIHEMOPROTEIN REDUCTASE; SULFONYLUREA DERIVATIVE; UNSPECIFIC MONOOXYGENASE;

ARTICLE; CONTROLLED STUDY; DIABETIC PATIENT; DISEASE DURATION; DNA POLYMORPHISM; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; GENETIC RISK; GENETIC VARIABILITY; HUMAN; HYPOGLYCEMIA; INSULIN DEPENDENT DIABETES MELLITUS; KIDNEY FUNCTION; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REAL TIME POLYMERASE CHAIN REACTION; RISK ASSESSMENT; ALLELE; CASE CONTROL STUDY; CHEMICALLY INDUCED DISORDER; GENE FREQUENCY; GENETIC PREDISPOSITION; GENETICS; GENOTYPE; RISK FACTOR;

ALLELES; ARYL HYDROCARBON HYDROXYLASES; CASE-CONTROL STUDIES; DIABETES MELLITUS, TYPE 2; FEMALE; GENE FREQUENCY; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HUMANS; HYPOGLYCEMIA; HYPOGLYCEMIC AGENTS; MALE; NADPH-FERRIHEMOPROTEIN REDUCTASE; RISK FACTORS; SULFONYLUREA COMPOUNDS;

EID: 84893049538     PISSN: 09477349     EISSN: 14393646     Source Type: Journal    
DOI: 10.1055/s-0033-1361097     Document Type: Article

References (17)

1. Chao J., Nau D. P., Aikens J. E. Patient-reported perceptions of side effects of antihyperglycemic medication and adherence to medication regimens in persons with diabetes mellitus. Clinical Therapeutics: 2007; 29 177 180 (Pubitemid 46414033)
2. Manolopoulos V. G. Pharmacogenomics and adverse drug reactions in diagnostic and clinical practice. Clin Chem Lab Med: 2007; 45 801 814 (Pubitemid 47041905)
3. Kirchheiner J., Roots I., Goldammer M. et al. Effect of genetic polymorphisms in cytochrome p450 (CYP) 2C9 and CYP2C8 on the pharmacokinetics of oral antidiabetic drugs: clinical relevance. Clin Pharmacokinet: 2005; 44 1209 1225 (Pubitemid 41832564)
4. Manolopoulos V. G., Ragia G., Tavridou A. Pharmacogenomics of oral antidiabetic medications: current data and pharmacoepigenomic perspective. Pharmacogenomics: 2011; 12 1161 1191
5. Holstein A., Plaschke A., Ptak M. et al. Association between CYP2C9 slow metabolizer genotypes and severe hypoglycaemia on medication with sulphonylurea hypoglycaemic agents. Br J Clin Pharmacol: 2005; 60 103 106 (Pubitemid 40942788)
6. Ragia G., Petridis I., Tavridou A. et al. Presence of CYP2C93 allele increases risk for hypoglycemia in Type 2 diabetic patients treated with sulfonylureas. Pharmacogenomics: 2009; 10 1781 1787
7. Gokalp O., Gunes A., Cam H. et al. Mild hypoglycaemic attacks induced by sulphonylureas related to CYP2C9, CYP2C19 and CYP2C8 polymorphisms in routine clinical setting. Eur J Clin Pharmacol: 2011; 67 1223 1229
8. Rettie A. E., Wienkers L. C., Gonzalez F. J. et al. Impaired (S)-warfarin metabolism catalysed by the R144C allelic variant of CYP2C9. Pharmacogenetics: 1994; 4 39 42 (Pubitemid 24106122)
9. Johnson J. A., Klein T. E., Relling M. V. Clinical implementation of pharmacogenetics: more than one gene at a time. Clin Pharmacol Ther: 2013; 93 384 385
10. Subramanian M., Agrawal V., Sandee D. et al. Effect of P450 oxidoreductase variants on the metabolism of model substrates mediated by CYP2C9.1, CYP2C9.2, and CYP2C9.3. Pharmacogenet Genomics: 2012; 22 590 597
11. Fluck C. E., Nicolo C., Pandey A. V. Clinical, structural and functional implications of mutations and polymorphisms in human NADPH P450 oxidoreductase. Fundam Clin Pharmacol: 2007; 21 399 410 (Pubitemid 47084036)
12. Riddick D. S., Ding X., Wolf C. R. et al. NADPH-cytochrome P450 oxidoreductase: roles in physiology, pharmacology, and toxicology. Drug Metab Dispos: 2013; 41 12 23
13. Gomes A. M., Winter S., Klein K. et al. Pharmacogenomics of human liver cytochrome P450 oxidoreductase: multifactorial analysis and impact on microsomal drug oxidation. Pharmacogenomics: 2009; 10 579 599
14. Huang N., Agrawal V., Giacomini K. M. et al. Genetics of P450 oxidoreductase: sequence variation in 842 individuals of four ethnicities and activities of 15 missense mutations. Proc Natl Acad Sci USA: 2008; 105 1733 1738 (Pubitemid 351346583)
15. Ragia G., Tavridou A., Petridis I. et al. Association of KCNJ11 E23K gene polymorphism with hypoglycemia in sulfonylurea-treated type 2 diabetic patients. Diabetes Res Clin Pract: 2012; 98 119 124
16. Oneda B., Crettol S., Jaquenoud Sirot E. et al. The P450 oxidoreductase genotype is associated with CYP3A activity in vivo as measured by the midazolam phenotyping test. Pharmacogenet Genomics: 2009; 19 877 883
17. Yang G., Fu Z., Chen X. et al. Effects of the CYP oxidoreductase Ala503Val polymorphism on CYP3A activity in vivo: a randomized, open-label, crossover study in healthy Chinese men. Clin Ther: 2011; 33 2060 2070